Exploratory analyses of HER1/EGFR, K-ras mutations and other molecular markers in tumors of patients with non-small-cell lung cancer treated with chemotherapy with or without erlotinib (Tarceva) (talent—phase iii) [slideshow]
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.